Suppr超能文献

动物纤维化肝脏疾病模型:我们拥有的、需要的和正在开发的。

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.

机构信息

Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique (IREC), Catholic University of Louvain (UCL), Brussels, Belgium.

Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique (IREC), Catholic University of Louvain (UCL), Brussels, Belgium ; Department of Gastroenterology, Saint-Luc Academic Hospital and Institute of Clinical Research, Catholic University of Louvain, Brussels, Belgium.

出版信息

J Clin Transl Hepatol. 2015 Mar;3(1):53-66. doi: 10.14218/JCTH.2014.00035. Epub 2015 Mar 15.

Abstract

Liver fibrosis is part of the wound-healing response to liver damage of various origins and represents a major health problem. Although our understanding of the pathogenesis of liver fibrosis has grown considerably over the last 20 years, effective antifibrotic therapies are still lacking. The use of animal models is crucial for determining mechanisms underlying initiation, progression, and resolution of fibrosis and for developing novel therapies. To date, no animal model can recapitulate all the hepatic and extra-hepatic features of liver disease. In this review, we will discuss the current rodent models of liver injuries. We will then focus on the available ways to target specifically particular compounds of fibrogenesis and on the new models of liver diseases like the humanized liver mouse model.

摘要

肝纤维化是各种来源的肝损伤的伤口愈合反应的一部分,是一个主要的健康问题。尽管在过去的 20 年中,我们对肝纤维化发病机制的理解有了很大的提高,但仍然缺乏有效的抗纤维化治疗方法。动物模型的使用对于确定纤维化的起始、进展和消退的机制以及开发新的治疗方法至关重要。迄今为止,没有一种动物模型可以重现所有肝脏和肝脏外疾病的特征。在这篇综述中,我们将讨论目前用于肝脏损伤的啮齿动物模型。然后,我们将重点介绍针对特定纤维化化合物的靶向治疗方法,以及人类化肝脏小鼠模型等新型肝脏疾病模型。

相似文献

1
Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.
J Clin Transl Hepatol. 2015 Mar;3(1):53-66. doi: 10.14218/JCTH.2014.00035. Epub 2015 Mar 15.
2
Autophagy: A new therapeutic target for liver fibrosis.
World J Hepatol. 2015 Aug 8;7(16):1982-6. doi: 10.4254/wjh.v7.i16.1982.
3
Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin Liver Dis. 2001 Aug;21(3):437-51. doi: 10.1055/s-2001-17558.
4
Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy.
J Gastroenterol Hepatol. 1999 Jul;14(7):618-33. doi: 10.1046/j.1440-1746.1999.01928.x.
5
Hepatic fibrogenesis: from within and outwith.
Toxicology. 2008 Dec 30;254(3):130-5. doi: 10.1016/j.tox.2008.08.017. Epub 2008 Sep 7.
6
Hepatic Fibrosis in Dogs.
J Vet Intern Med. 2018 Jan;32(1):26-41. doi: 10.1111/jvim.14891. Epub 2017 Nov 30.
7
Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis.
Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):709-720. doi: 10.1016/j.bbadis.2017.12.008. Epub 2017 Dec 6.
9
Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.
Arch Toxicol. 2015 Oct;89(10):1727-50. doi: 10.1007/s00204-015-1525-6. Epub 2015 May 12.
10
Pathogenesis of liver fibrosis.
Annu Rev Pathol. 2011;6:425-56. doi: 10.1146/annurev-pathol-011110-130246.

引用本文的文献

2
A novel chronic hepatitis B mouse model with immune activation and liver fibrosis.
Microbiol Spectr. 2025 Jul 24:e0251324. doi: 10.1128/spectrum.02513-24.
4
Fibrosis: cross-organ biology and pathways to development of innovative drugs.
Nat Rev Drug Discov. 2025 Mar 18. doi: 10.1038/s41573-025-01158-9.
5
Mouse Models for the Study of Liver Fibrosis Regression and .
J Clin Transl Hepatol. 2024 Nov 28;12(11):930-938. doi: 10.14218/JCTH.2024.00212. Epub 2024 Oct 11.
7
Modulation of liver cholesterol homeostasis by choline supplementation during fibrosis resolution.
Heliyon. 2024 Aug 31;10(17):e36727. doi: 10.1016/j.heliyon.2024.e36727. eCollection 2024 Sep 15.
8
Diabetes mellitus-Progress and opportunities in the evolving epidemic.
Cell. 2024 Jul 25;187(15):3789-3820. doi: 10.1016/j.cell.2024.06.029.
9
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension.
iScience. 2024 Feb 20;27(3):109301. doi: 10.1016/j.isci.2024.109301. eCollection 2024 Mar 15.
10
Human Precision-Cut Liver Slices: A Potential Platform to Study Alcohol-Related Liver Disease.
Int J Mol Sci. 2023 Dec 21;25(1):150. doi: 10.3390/ijms25010150.

本文引用的文献

1
CRISPR-mediated direct mutation of cancer genes in the mouse liver.
Nature. 2014 Oct 16;514(7522):380-4. doi: 10.1038/nature13589. Epub 2014 Aug 6.
2
Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.
Int J Exp Pathol. 2014 Oct;95(5):309-20. doi: 10.1111/iep.12090. Epub 2014 Aug 12.
3
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.
Front Pharmacol. 2014 Jul 22;5:167. doi: 10.3389/fphar.2014.00167. eCollection 2014.
4
Experimental models of non-alcoholic fatty liver disease in rats.
World J Gastroenterol. 2014 Jul 14;20(26):8364-76. doi: 10.3748/wjg.v20.i26.8364.
5
Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges.
Am J Physiol Gastrointest Liver Physiol. 2014 May 15;306(10):G819-23. doi: 10.1152/ajpgi.00041.2014. Epub 2014 Apr 3.
6
7
Characterization of animal models for primary sclerosing cholangitis (PSC).
J Hepatol. 2014 Jun;60(6):1290-303. doi: 10.1016/j.jhep.2014.02.006. Epub 2014 Feb 19.
8
Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration.
PLoS One. 2013 Dec 17;8(12):e84071. doi: 10.1371/journal.pone.0084071. eCollection 2013.
9
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.
Fibrogenesis Tissue Repair. 2013 Oct 1;6(1):19. doi: 10.1186/1755-1536-6-19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验